

(19) **DANMARK**



Patent- og  
Varemærkestyrelsen

(12)

## Oversættelse af europæisk patentskrift

(10) **DK/EP 2977088 T3**

- 
- (51) Int.Cl.: **C 07 K 14/31 (2006.01)** **C 07 K 16/06 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-10-09**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2017-08-02**
- (86) Europæisk ansøgning nr.: **15181524.8**
- (86) Europæisk indleveringsdag: **2011-03-07**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-01-27**
- (30) Prioritet: **2010-03-08 EP 10155835**
- (62) Stamansøgningsnr: **11707162.1**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **GE Healthcare BioProcess R&D AB, Björkgatan 30, 751 84 Uppsala, Sverige**
- (72) Opfinder: **ABRAHMSÉN, Lars, Vereliusvägen 17, 168 53 Bromma, Sverige**
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**
- (54) Benævnelse: **IMMUNOGLOBULIN G FC-REGION-BINDENDE POLYPEPTID**
- (56) Fremdragne publikationer:  
**WO-A1-2009/146755**  
**US-A- 5 143 844**  
**US-A1- 2005 147 962**  
**US-A1- 2006 194 955**  
**NILSSON B ET AL: "A synthetic IgG-binding domain based on staphylococcal protein A", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 1, no. 2, 1 January 1987 (1987-01-01) , pages 107-113, XP002133892, ISSN: 0269-2139**  
**LINHULT MARTIN ET AL: "Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach", PROTEINS: STRUCTURE, FUNCTION AND GENETICS, JOHN WILEY & SONS, INC, US, vol. 55, no. 2, 1 May 2004 (2004-05-01), pages 407-416, XP002488610, ISSN: 0887-3585, DOI: DOI:10.1002/PROT.10616**  
**SAITO A ET AL: "HIGH LEVEL EXPRESSION OF A SYNTHETIC GENE CODING FOR IGG-BINDING DOMAIN B OF STAPHYLOCOCCAL PROTEIN A", PROTEIN ENGINEERING, vol. 2, no. 6, 1989, pages 481-488, XP009148242, ISSN: 0269-2139**  
**LI N ET AL: "Factors affecting cleavage at aspartic residues in model decapeptides", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 50, no. 1, 15 August 2009 (2009-08-15), pages 73-78, XP026133458, ISSN: 0731-7085, DOI: DOI:10.1016/J.JPBA.2009.03.020 [retrieved on 2009-03-28]**  
**TAVERNA D M ET AL: "Why are proteins so robust to site mutations?", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 315, no. 3, 18 January 2002 (2002-01-18), pages 479-484, XP004469322, ISSN: 0022-2836, DOI: DOI:10.1006/JMBI.2001.5226**

Fortsættes ...



# DESCRIPTION

## Field of the invention

**[0001]** This invention relates to a polypeptide which binds to immunoglobulin G Fc (IgG Fc), and to methods for its production. The polypeptide has industrial application for example in separation and/or purification in the production of antibodies and/or Fc fusion proteins, e.g. in chromatography.

## Background

**[0002]** In the industrial production of monoclonal antibodies and Fc fusion proteins, purification is frequently carried out using chromatography. Protein A from *Staphylococcus aureus* has long been used as affinity ligand in such applications, due to the native affinity of Protein A for the Fc portion of IgG. Protein A in its entirety, as well as the five individual Fc-binding domains thereof, have subsequently served as starting points for the rational design of engineered affinity ligands with improved properties.

**[0003]** For example, the B domain of Protein A served as a starting point for the creation of the engineered, IgG Fc-binding, single-domain protein Z (Nilsson B et al, Protein Eng 1(2):107-13, 1987). In order to improve the stability of this protein in alkaline conditions, such as those employed in cleaning-in-place procedures during industrial chromatographic processes, Linhult et al (Proteins 55(2):407-16, 2004) proposed a variant of protein Z comprising mutated asparagine residues. This variant was further developed by GE Healthcare, Uppsala, Sweden, into the commercial product MAbSelect™ SuRe. Additional Z variants with IgG Fc affinity are disclosed in WO2009/146755.

**[0004]** Mutated binding proteins based on protein Z, in which the native IgG Fc binding has been modified, are described in WO2009/080811 and US5,143,844A. IgG Fc region-binding polypeptides that can be produced through cleavage of multimers are disclosed in SAITO A et al. (Protein Engineering 2(6):481-488, 1989).

**[0005]** Native Protein A, with its five individual IgG Fc-binding domains, has been shown to bind only 2 molecules of IgG, or 3 molecules of recombinant Fc-fragment, despite the fact that each of the five domains has the capacity to bind one IgG (Birger Jansson, PhD Thesis, Stockholm, Sweden, 1996, ISBN 91-7170-656-9).

**[0006]** Despite the comparable success of currently used IgG Fc affinity ligands, there is a continued need for improvement, especially with regard to the combined requirements of improving stoichiometry and at the same time maintaining, and ideally improving, stability towards acidic and alkaline conditions. The continued provision of agents with affinity for IgG

Fc remains a matter of substantial interest.

### Summary of the invention

**[0007]** According to a first aspect thereof, the invention provides an immunoglobulin G Fc (IgG Fc) binding polypeptide, comprising the amino acid sequence

1. i)  $X_1$ -([*spacer1*]-KFDKEQQN AFYEIL $X_{17}$ LP $X_{20}$  LTEEQRNAFI QKLKDX $X_{36}$ PSQS AELLAEAKQL  $X_{51}$ EAQA-[*spacer2*]) $_n$ -C<sub>CTERM</sub>-1 $X_{CTERM}$  wherein, independently of each other,

$X_1$  is P;

[*spacer1*] is an amino acid sequence consisting of 1-3 amino acid residues;

$X_{17}$  is any amino acid residue;

$X_{20}$  is any amino acid residue;

$X_{36}$  is E or A;

$X_{51}$  is any amino acid residue;

[*spacer2*] is an amino acid sequence consisting of 0-20 amino acid residues;

$X_{CTERM}$  is D; and

$n$  is 1-4.

**[0008]** In an embodiment of this aspect of the invention, the immunoglobulin G Fc (IgG Fc) binding polypeptide consists of an amino acid sequence selected from i) as defined above.

**[0009]** The amino acid sequence of the polypeptide according to the invention has been conceived by the present inventor in order to provide an optimized IgG Fc-binding molecule, taking as the starting point the various domains of Protein A from *Staphylococcus* as well as protein Z, derived from the B domain of Protein A. Similar to the modular domain structure of natural Protein A or previously known engineered variants thereof, the polypeptide of the present invention provides one or more distinct domains possessing IgG Fc-binding capacity. In particular, the amino acid sequence between the two *spacer* sequences is predicted to fold into a single, three-helical bundle domain with IgG Fc-binding capacity. As described above, the number  $n$  may be between 1 and 4, signifying that a polypeptide according to the invention may have from one to four distinct IgG Fc-binding domains separated by the *spacer* sequences, making up a monomer, dimer, trimer or tetramer of such domains.

**[0010]** In protein Z, the amino acid position corresponding to position 17 in amino acid sequence i) above is occupied by a histidine residue. In the inventive polypeptide, X<sub>17</sub> may be H, but may also be substituted by any other amino acid residue. Substitution at this position may be motivated by the general need to avoid chemically reactive amino acids.

**[0011]** In protein Z, the amino acid position corresponding to position 36 in amino acid sequence i) above is occupied by an aspartic acid residue. In the amino acid sequence i), however, this position is substituted for example by a glutamic acid residue or an alanine residue. Without wishing to be bound by theory, this difference is presently thought to serve the two separate purposes of a) increasing the acid stability of the polypeptide and b) removing a DP dipeptide within the three-helix bundle domain, which would otherwise be susceptible to acid catalyzed cleavage. One aspect of the invention, described in more detail below, uses the susceptibility of the DP dipeptide motif in another part of the molecule, and the presence of a DP dipeptide at positions 36-37 would diminish the practicality of this aspect of the invention.

**[0012]** In protein Z, the amino acid position corresponding to position 49 in amino acid sequence i) above is occupied by a lysine residue. In the amino acid sequence i), however, this position is occupied by a glutamine residue.

**[0013]** As the skilled person will realize, the function of any polypeptide, such as the IgG Fc-binding capacity of the polypeptides according to the invention, is dependent on the tertiary structure of the polypeptide. It is possible to make changes to the sequence of amino acids in an  $\alpha$ -helical polypeptide without affecting the function thereof (Taverna and Goldstein, J Mol Biol 315(3):479-84, 2002; He et al, Proc Natl Acad Sci USA 105(38):14412-17, 2008). Thus, the disclosure encompasses modified variants of i), which are such that the resulting sequence is at least 95 % identical to a sequence belonging to the class defined by i). For example, it is possible that an amino acid residue belonging to a certain functional grouping of amino acid residues (e.g. hydrophobic, hydrophilic, polar etc) could be exchanged for another amino acid residue from the same functional group.

**[0014]** When reference is made herein to the degree of identity between the amino acid sequences of different polypeptides, the lower limit of 95 % identity to a sequence disclosed herein is given. In some embodiments, the inventive polypeptide may have a sequence which is at least 96 %, at least 97 %, at least 98 % or at least 99 % identical to the sequence described herein. The term "% identity", as used throughout the specification and the appended claims, may for example be calculated as follows. The query sequence is aligned to the target sequence using the CLUSTAL W algorithm (Thompson, J.D., Higgins, D.G. and Gibson, T.J., Nucleic Acids Research, 22: 4673-4680 (1994)). A comparison is made over the window corresponding to the shortest of the aligned sequences. The shortest of the aligned sequences may in some instances be the target sequence, such as the 29 amino acid residue HER3 binding motif. In other instances, the query sequence may constitute the shortest of the aligned sequences. The query sequence may for example consist of at least 10 amino acid residues, such as at least 20 amino acid residues. The amino acid residues at each position

are compared, and the percentage of positions in the query sequence that have identical correspondences in the target sequence is reported as % identity.

**[0015]** In one embodiment of the polypeptide according to the invention, *[spacer1]* is selected from A, AE and AEA. *[spacer1]* may for example be A.

**[0016]** In one embodiment of the polypeptide according to the invention, X<sub>17</sub> is H.

**[0017]** In one embodiment of the polypeptide according to the invention, X<sub>20</sub> is any amino acid residue except for N. X<sub>20</sub> may for example be T.

**[0018]** In an alternative embodiment, X<sub>20</sub> is N.

**[0019]** In the polypeptide according to the invention, X<sub>36</sub> is selected from E and A. X<sub>36</sub> may for example be E.

**[0020]** In one embodiment of the polypeptide according to the invention X<sub>51</sub> is any amino acid residue except for N. X<sub>51</sub> may for example be D.

**[0021]** In an alternative embodiment, X<sub>51</sub> is N.

**[0022]** In one embodiment of the polypeptide according to the invention, all amino acid residues of *[spacer2]* are independently selected from A, E, F, G, I, K, L, P, Q, R, S, T and V, in particular from A, E, G, K, P, Q, R, S and T, such as from G, Q and S. In an even more specific embodiment, *[spacer2]* is G.

**[0023]** As discussed above, n is a number between 1 and 4, i.e. it may be 1, 2, 3 or 4.

**[0024]** In polypeptides according to the invention wherein  $n > 1$ , the multiple occurrences of *[spacer1]* may each individually consist of the same amino acid sequence or be different amino acid sequences. Likewise, in polypeptides according to the invention wherein  $n > 1$ , the multiple occurrences of *[spacer2]* may each individually consist of the same amino acid sequence or be different amino acid sequences.

**[0025]** An IgG Fc-binding polypeptide according to any aspect of the invention may bind to IgG Fc such that the K<sub>D</sub> value of the interaction is at most  $1 \times 10^{-6}$  M, for example at most  $1 \times 10^{-7}$  M, such as at most  $5 \times 10^{-8}$  M.

**[0026]** The polypeptide is advantageous in that it binds well to an IgG Fc. In particular, the polypeptide may be capable of binding to the Fc portion of a human IgG molecule. In some embodiments of the invention, the polypeptide is capable of binding to classes 1, 2 and 4 of human IgG, but not to class 3. In some embodiments, the polypeptide is capable of binding to

the interface between the CH2 and CH3 domains of IgG Fc.

**[0027]** In one embodiment of the IgG Fc-binding polypeptide according to the invention,  $X_1$  is P.

**[0028]** In one embodiment of the IgG Fc-binding polypeptide according to the invention,  $X_{CTERM}$  is D.

**[0029]** In a particular embodiment of the IgG Fc-binding polypeptide according to the invention,  $X_1$  is P and  $X_{CTERM}$  is D.

**[0030]** In one embodiment of the polypeptide according to the disclosure, the amino acid sequence i) is selected from SEQ ID NO:1-6 of the appended Figure 1. It may for example be SEQ ID NO:1. As readily apparent,  $n = 1$  for the sequences SEQ ID NO:1-2, and  $n = 2$  for the sequences SEQ ID NO:3-6. It is also evident from the sequences themselves that SEQ ID NO:1-4 are examples of the embodiment in which  $X_1$  is P and  $X_{CTERM}$  is D, whereas SEQ ID NO:5-6 are examples of another embodiment.

**[0031]** In a related aspect, the disclosure provides a polynucleotide comprising a nucleotide sequence encoding any polypeptide according to the first aspect of the invention.

**[0032]** As explained above, in the polypeptide according to the first aspect of the invention,  $X_1$  is P and  $X_{CTERM}$  is D in the amino acid sequence thereof. This design of the N- and C-terminal amino acid residues enables a convenient approach to the production of the IgG Fc-binding polypeptide by recombinant DNA technology, by first producing a multimer having copies of the inventive polypeptide as subunits, each subunit being separated from the others via the dipeptide DP. The amino acid sequence DP is susceptible to acid catalyzed hydrolysis, so the dipeptide site between subunits may be used as a cleavage site for separation of the subunits in the multimer from each other. As non-limiting examples, the multimer may comprise 2-6 subunits, such as 4 subunits or 6 subunits. In this regard, it is pointed out that the subunits making up the multimer may themselves comprise from 1 to 4 distinct IgG Fc-binding domains, as disclosed above with regard to the number  $n$  in the sequence of i). The subunits separated by DP sequences and the single IgG Fc-binding domains may constitute the same structural elements in the multimer (i.e. if  $n = 1$ ), but may also constitute different structural elements of the construct (if  $n = 2-4$ ).

**[0033]** Thus, in a second aspect of the present invention, there is provided a multimer polypeptide comprising

- at least two subunits, each subunit being a polypeptide according to the first aspect wherein  $X_1$  is P and  $X_{CTERM}$  is D; and
- an N-terminal leader peptide comprising a D residue as the last residue thereof.

**[0034]** Thus, in order to provide a DP dipeptide suitable for cleavage, the N-terminal leader peptide has to comprise a D residue as the last residue thereof. In the multimer polypeptide, this D residue forms a DP dipeptide together with the P<sub>1</sub> residue of the first subunit. The exact sequence of the remainder of the N-terminal leader peptide is not critical for the invention, as long as any amino acid residue preceding the D residue does not interfere with cleavage of the DP dipeptide. The beginning of the leader peptide will depend on the expression system used for production. For example, intracellular expression may be used to yield a leader peptide of MD from which the M is then removed *in vivo*, from a soluble protein. If the expression is driven towards formation of inclusion bodies, a leader peptide of MXGD may be used, wherein X may be any amino acid or G or excluded.

**[0035]** The disclosure also provides a polynucleotide, which comprises a nucleotide sequence encoding a multimer polypeptide as described immediately above.

**[0036]** The present disclosure provides, in yet a related aspect, a method of producing a multimer polypeptide as described above, which method comprises:

- providing a host cell harboring an expression vector comprising a polynucleotide comprising a nucleotide sequence encoding a multimer as described above,
- culturing the host cell under conditions that enable the expression of said polynucleotide into a multimer polypeptide, and
- isolating the resulting multimer polypeptide.

**[0037]** Once the resulting multimer polypeptide has been isolated, it may be used as starting material for the production of the IgG Fc-binding polypeptides of the first aspect of the invention, since these polypeptides are present as the subunits of the multimer. Thus, the disclosure also provides a method of producing a polypeptide according to the first aspect, which method comprises:

- producing a multimer polypeptide using the method described immediately above,
- cleaving the multimer polypeptide at sites comprising the sequence DP using acid-catalyzed hydrolysis, yielding IgG Fc-binding polypeptides according to the first aspect of the invention and N-terminal leader peptide, and
- isolating said IgG Fc-binding polypeptides.

**[0038]** Whether or not they comprise DP sequences and whether or not they are prepared according to the convenient approach described in the previous section, any polypeptide according to the disclosure comprises a cysteine residue at the penultimate position C<sub>CTERM-1</sub> (which is in fact the ultimate position if X<sub>CTERM</sub> is not present). The incorporation of this cysteine residue into the amino acid sequence of the inventive polypeptide enables highly



versatile chemical coupling of the polypeptide to other compounds. Using this cysteine residue to couple the polypeptide, directly or indirectly, to a matrix, enables the production of a separation medium useful for industrial-scale separation of IgG Fc-containing molecules, for example in a process for production of monoclonal antibodies. The affinity ligand in the separation medium or chromatography medium is the IgG Fc-binding polypeptide according to the first aspect of the invention. The matrix may be made from an organic or inorganic material. In one embodiment, the matrix is prepared from a native polymer, such as cross-linked carbohydrate material, e.g. agarose, agar, cellulose, dextran, chitosan, konjac, carrageenan, gellan, alginate etc. The native polymer matrices are easily prepared and optionally cross-linked according to standard methods, such as inverse suspension gelation (S Hjertén (1964), *Biochim Biophys Acta* 79(2):393-398). In an alternative embodiment, the matrix is prepared from a synthetic polymer or copolymer, such as cross-linked synthetic polymers, e.g. styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides etc. Such synthetic polymer matrices are easily prepared and optionally cross-linked according to standard methods. As non-limiting examples of direct coupling to a matrix, the IgG Fc-binding polypeptide may be attached via C<sub>CTERM-1</sub> to a maleimide agarose, iodoacetyl sepharose or agarose, e.g. SulfoLink® from Pierce. As a non-limiting example of indirect coupling, the IgG Fc-binding polypeptide may be attached via C<sub>CTERM-1</sub> to a linker polymer, forming an intermediate, IgG Fc-binding composition. This intermediate composition may then in turn be coupled to a matrix via reactive groups in either the IgG Fc-binding polypeptide or in the linker polymer.

**[0039]** Preferred linker polymers are stable, both against acid and base catalyzed hydrolysis as well as against proteolytic degradation. They are hydrophilic, and of non-nucleic acid and non-peptidic origin. From a regulatory point of view, preferred polymers are those that have been previously used *in vivo*, but the invention is not limited thereto. A particularly preferred linker polymer is poly(ethylene glycol), PEG. The length of linker polymer between coupled IgG Fc-binding polypeptides should be sufficient to allow 1:1 stoichiometry of the interaction between IgG Fc-containing molecules and each Fc-binding domain.

**[0040]** In the inventive IgG Fc-binding composition, the stability towards acid or base catalyzed hydrolysis is ensured by joining the folded domains using a chemically stable linker polymer.

**[0041]** Thus, in another aspect thereof, the invention provides an IgG Fc-binding composition, comprising at least one IgG Fc-binding polypeptide according to the first aspect, covalently coupled to a non-peptide, non-nucleic acid linker polymer via the cysteine residue C<sub>CTERM-1</sub>.

**[0042]** In a related aspect, the disclosure provides a method of producing such an IgG Fc-binding composition. The method comprises:

- providing at least one IgG Fc-binding polypeptide according to the first aspect, and
- coupling said polypeptide to a non-peptide, non-nucleic acid linker polymer via the cysteine residue C<sub>CTERM-1</sub> present in said polypeptide.

**[0043]** The number of IgG Fc-binding polypeptides coupled to each molecule of polymer linker may be determined by design, for example by using a predetermined mixture of polymer molecules adapted for conjugation with different numbers of IgG Fc-binding polypeptides. For example, a polymer having 1-4 conjugation sites for IgG Fc-binding polypeptides may be used in the preparation of a homogeneous IgG Fc-binding composition, or a mixture of polymers having 1-4 conjugation sites may be used to prepare the corresponding Fc-binding composition.

**[0044]** In the case where the IgG Fc-binding polypeptide comprises the P<sub>1</sub> and D<sub>CTERM</sub> amino acid residues, the provision in the first step of this production method may be done according to the description above of a method of producing such polypeptides as subunits in a multimer, which subunits are separated by DP sequences amenable to cleavage by acid catalyzed hydrolysis. In other words, in this embodiment of the invention, a composition for use as affinity ligand in a chromatography medium may be prepared by i) expressing a multimer comprising the individual IgG Fc-binding polypeptides (whether mono-, di-, tri- or tetrameric) as subunits, ii) cleaving the multimer into its constituent subunits by acid catalyzed hydrolysis, iii) coupling the resulting subunits (i.e. the IgG Fc-binding polypeptides according to the invention) to the linker polymer via the C<sub>CTERM-1</sub> residue.

**[0045]** In some embodiments of the inventive composition and methods of producing it described above, the linker polymer is poly(ethylene glycol).

**[0046]** The composition according to the invention may suitably be connectable to a matrix or chromatography medium via the linker polymer. The chemical nature of the group used for attachment of the composition to the matrix is preferably different from that of the group used for conjugation of the IgG Fc-binding polypeptides to the linker polymer. Thanks to the stability of the IgG Fc-binding polypeptides according to the invention with regard to both acidic and basic conditions, activation of a reacting group may be done either by base or acid. The length of polymer between the matrix and the most proximal IgG Fc-binding polypeptide should not interfere with IgG binding properties of this domain. The choice between available coupling chemistries and adaptation of them to the present invention is within the abilities of the skilled person.

**[0047]** The terms "IgG Fc-binding" and "binding affinity for IgG Fc" as used in this specification refers to a property of a polypeptide which may be tested for example by the use of surface plasmon resonance technology, such as in a Biacore instrument (GE Healthcare). For example as described in the examples below, IgG Fc-binding affinity may be tested in an experiment in which IgG Fc, or a fragment of IgG Fc, is immobilized on a sensor chip of the instrument, and the sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the instrument, and a sample containing IgG Fc, or fragment thereof, is passed over the chip. The skilled person may then

interpret the results obtained by such experiments to establish at least a qualitative measure of the binding affinity of the polypeptide for IgG Fc. If a quantitative measure is desired, for example to determine a  $K_D$  value for the interaction, surface plasmon resonance methods may also be used. Binding values may for example be defined in a Biacore 2000 instrument (GE Healthcare). IgG Fc is immobilized on a sensor chip of the measurement, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution and injected in random order.  $K_D$  values may then be calculated from the results using for example the 1:1 Langmuir binding model of the BIAevaluation 4.1 software provided by the instrument manufacturer.

**[0048]** Where amino acid substitutions are introduced, these should not affect the basic structure of the polypeptide. For example, the overall folding of the C $\alpha$  backbone of the polypeptide can be essentially the same as that of a domain of Protein A, i.e. having the same elements of secondary structure in the same order. Thus, polypeptides having this basic structure will have CD spectra that are similar to that of a wild-type Protein A domain. The skilled addressee is aware of other parameters that may be relevant. The requirement of conserving the basic structure places restrictions on which positions of the amino acid sequence may be subject to substitution. For example, it is preferred that amino acid residues located on the surface of the polypeptide are substituted, whereas amino acid residues buried within the core of the polypeptide "three-helix bundle" should be kept constant in order to preserve the structural properties of the molecule. The same reasoning applies to fragments of polypeptides of the invention.

**[0049]** Thus, the invention also covers polypeptides and compositions in which the IgG Fc-binding polypeptide described above is present as an IgG Fc-binding domain to which additional amino acid residues have been added at either terminal. These additional amino acid residues may play a role in the binding of IgG Fc by the polypeptide, but may equally well serve other purposes, related for example to one or more of the production, purification, stabilization *in vivo* and/or *in vitro*, coupling or detection of the polypeptide. Such additional amino acid residues may comprise one or more amino acid residues added for the purpose of chemical coupling. Such additional amino acid residues may provide a "tag" for purification or detection of the polypeptide such as a His<sub>6</sub> tag or a "myc" (c-myc) tag or a "FLAG" tag for interaction with antibodies specific to the tag.

**[0050]** The present invention also covers IgG Fc-binding polypeptides in which an IgG Fc-binding polypeptide as described above is present as an IgG Fc-binding domain to which additional peptides or proteins or other functional groups are coupled N- or C-terminally or to any other residues (specifically or non-specifically) by means of chemical conjugation (using known organic chemistry methods).

**[0051]** A polypeptide according to the invention may be useful in any method which relies on affinity for IgG Fc of a reagent. Thus, the polypeptide may be used as a detection reagent, a capture reagent or a separation reagent in such methods. In particular, as already stated above, the polypeptide exhibits several characteristics which make it useful as an affinity

reagent in chromatography, wherein the goal is to separate, purify and/or produce antibodies or Fc fusion proteins from a heterogeneous mixture. The polypeptide can be bound to a matrix and e.g. used for the purification of IgG Fc-containing therapeutic compounds in industrial production. Due to properties such as a high target affinity, a high stability both in acidic and basic environments and selectivity for the IgG Fc fragment over the IgG Fab fragment, the IgG Fc-binding polypeptide according to the invention is thought to present a very attractive affinity reagent.

**[0052]** Thus, another aspect of the present invention is a method of isolating molecules comprising IgG Fc from a liquid, which method comprises the steps:

1. (i) providing a liquid containing molecules comprising IgG Fc;
2. (ii) contacting the liquid with an IgG Fc-binding polypeptide or composition as described herein, whereby said molecules comprising IgG Fc bind to the polypeptide or composition;
3. (iii) isolating bound molecules comprising IgG Fc from the liquid.

**[0053]** In the inventive isolation method, the liquid may be derived from a culture of prokaryotic or eukaryotic, such as mammalian or plant, cells expressing molecules comprising IgG Fc, or from expression of such molecules in an alternative expression system, for example a vesicular system. Alternatively, the liquid may be derived from transgenic expression in a host, such as a plant or mammalian host.

**[0054]** In the context of the present invention, the terms "sample" and "liquid" may be used interchangeably. Neither term implies any limitations, for example with regard to the volume of liquid involved or other characteristics. The liquid may be of a small volume, such as an aliquot of a larger volume, e.g. for analytical purposes; or alternatively, the feed or liquid used in a large scale purification process.

**[0055]** In some embodiments, said molecules comprising IgG Fc are IgG molecules or fragments thereof. For example, they can be human IgG molecules or fragments thereof. In some embodiments, said molecules comprising IgG Fc are monoclonal IgG antibodies. In particular, such monoclonal IgG antibodies may be human monoclonal IgG antibodies. For example, they are human monoclonal IgG antibodies from class 1, 2 and/or 4.

**[0056]** In other embodiments, said molecules comprising IgG Fc are Fc fusion proteins. The Fc domain in such a fusion protein may thus, advantageously, be used as an "affinity handle" in the isolation of the fusion protein. A large variety of Fc fusion proteins have been created. For example, Fc fusion proteins having therapeutic applications include etanercept, which is a fusion between soluble TNF- $\alpha$  receptor and Fc, and VEGF Trap, which is a fusion between VEGF receptor domains and Fc (Holash et al, Proc Natl Acad Sci USA (2002) 99(17):11393-11398). While these two are illustrative examples of great interest, the listing of them is non-limiting, and it is in principle possible to fuse an Fc domain to any desired protein in order to

modify its properties and facilitate affinity purification thereof using the inventive IgG Fc-binding polypeptide or composition described herein as affinity ligand.

**[0057]** Yet another aspect of the present disclosure concerns a method of producing molecules comprising IgG Fc, which method comprises the steps:

1. (i) expressing desired molecules comprising IgG Fc;
2. (ii) obtaining a liquid containing molecules comprising IgG Fc from said expression;
3. (iii) contacting the liquid with an IgG Fc-binding polypeptide or composition as described herein, whereby molecules comprising IgG Fc bind to the polypeptide or composition;
4. (iv) isolating bound molecules comprising IgG Fc from the liquid, and
5. (v) recovering bound molecules comprising IgG Fc through elution thereof from the IgG Fc-binding polypeptide or composition.

**[0058]** Expression step (i) may be performed using any known expression system, for example recombinant expression in prokaryotic or eukaryotic, such as mammalian or plant, cells, or in a vesicular system. The liquid may also be derived from transgenic expression in a host, such as a plant or mammalian host.

**[0059]** In some embodiments, said molecules comprising IgG Fc are IgG molecules or fragments thereof. For example, they can be human IgG molecules or fragments thereof. In some embodiments, said molecules comprising IgG Fc are monoclonal IgG antibodies. In particular, such monoclonal IgG antibodies may be human monoclonal IgG antibodies. For example, they are human monoclonal IgG antibodies from class 1, 2 and/or 4.

**[0060]** In other embodiments, said molecules comprising IgG Fc are Fc fusion proteins.

**[0061]** In some embodiments of the inventive methods of isolating and producing, the IgG Fc-binding polypeptide or composition is immobilized on a matrix. In one embodiment, the present polypeptide or composition has been coupled to a matrix in the form of an insoluble carrier. Such a carrier may be one or more particles, such as beads, e.g. a chromatography resin; or irregular shapes; membranes; filters; capillaries; monoliths; and any other format commonly used in protein separation and/or purification. Thus, in general, methods that employ the polypeptides and/or compositions in accordance with the invention *in vitro* may be performed in different formats, such as on filters or membranes, microtitre plates, in protein arrays, on biosensor surfaces, on beads, in flow cytometry, on tissue sections, and so on. In a specific aspect, the invention provides a chromatography medium, which has an IgG Fc-binding polypeptide or composition as described herein immobilized thereon. Such a medium may be based on any known chromatography material as a matrix, and coupling of the polypeptide or composition to the matrix may be performed using any one of several known procedures.

**[0062]** The numbering of amino acid residues and any use of the term "position" in the sequence of the polypeptide according to the invention is relative. In a polypeptide in

accordance with the invention which has as many amino acid residues as a specifically disclosed polypeptide, i.e. those described above, the positions of amino acids in the polypeptide correspond exactly to those in the disclosed polypeptides. In a situation where there is, for example, an N terminal extension compared to the disclosed polypeptides, those amino acid residues in the extended peptide that correspond to those of the non-extended peptide have the same position numbers. For example, if there is a six amino acid residue extension on the extended polypeptide, then amino acid number seven of that modified polypeptide, counting from the N terminus, corresponds to the amino acid in position number one of the disclosed polypeptide.

**[0063]** The invention is further illustrated by the following non-limiting examples.

#### **Brief description of the figures**

##### **[0064]**

Figure 1 is a table showing amino acid sequence information for polypeptides described herein. SEQ ID NO:1-6 are non-limiting examples of polypeptides according to the invention, whereas SEQ ID NO:7-9 are disclosed for illustrative and/or comparative purposes.

Figure 2 is a chromatogram from HPLC/MSD analysis of a sample of His<sub>6</sub>-Z05494 after treatment with 5 M phosphoric acid. The peak denoted I corresponds to cleaved (7052 Da), uncleaved (9179 Da) and modified (7268 Da) His<sub>6</sub>-Z05494 molecule.

Figure 3 is a chromatogram from HPLC/MSD analysis of a sample of His<sub>6</sub>-Z05494 after treatment with 2 M hydrochloric acid for 1 h at 50 °C. The peak denoted I corresponds to cleaved (7052 Da), uncleaved (9179 Da) and modified (7268 Da) His<sub>6</sub>-Z05494 molecule. The peak denoted II corresponds to hexahistidyl tag (2145 Da).

Figure 4 is a chromatogram from HPLC/MSD analysis of a sample of His<sub>6</sub>-Z05494 after treatment with 6 M phosphoric acid for 1 h at 50 °C. The peak denoted I corresponds to cleaved (7052 Da) and uncleaved (9179 Da) His<sub>6</sub>-Z05494 molecule.

#### **Example 1**

##### **Cleavage of a DP dipeptide sequence**

**[0065]** The HER2 binding Affibody® molecule Z05494 (SEQ ID NO:8 in Figure 1) was constructed starting from Z02891 (SEQ ID NO:7 in Figure 1) by replacing the aspartic acid in

position 37 of Z02891 to a glutamic acid. Z05494 was then used in the experiment described herein for illustrative purposes. The mutated gene was inserted into an expression vector containing the T7 promoter and encoding a hexahistidine (His<sub>6</sub>) tail followed by a DP dipeptide sequence enabling acid cleavage. The expressed protein, which had the amino acid sequence SEQ ID NO:9 (Figure 1) and was denoted His<sub>6</sub>-Z05494, was harvested as a soluble product with the starting methionine removed.

**[0066]** After expression, the cells were lysed by heating and the soluble His<sub>6</sub>-Z05494 product was purified by IMAC followed by reverse phase chromatography. The protein was aliquoted into vials in 1 mg and 5 mg portions and lyophilized.

**[0067]** A dilution series of 12 M, 10 M, 8 M, 6 M, 4 M, 2 M and 0.2 M was prepared for each of the following seven acids: phosphoric acid (H<sub>3</sub>PO<sub>4</sub>), acetic acid (CH<sub>3</sub>COOH), formic acid (HCOOH), sulfuric acid (H<sub>2</sub>SO<sub>4</sub>), hydrochloric acid (HCl), nitric acid (HNO<sub>2</sub>) and trifluoroacetic acid (CF<sub>3</sub>CO<sub>2</sub>H). Lyophilized His<sub>6</sub>-Z05494 was diluted in de-ionized water to a final concentration of 4 mg/ml. Seven eppendorf tubes per acid, all containing 25 µl His<sub>6</sub>-Z05494, were prepared. 25 µl of acid were added to the eppendorf tubes and left to incubate at 37 °C for 17 h 30 min (overnight).

**[0068]** Acid catalyzed cleavage was stopped by increasing the pH to 7.5-8.5 by addition of different concentrations of NaOH and 125 µl 2 M Tris-HCl, pH 8. All samples were analyzed with SDS-PAGE and loaded onto an HPLC/MSD equipment.

**[0069]** Analysis by HPLC/MSD showed that the weak acids acetic acid and formic acid cleaved a very small amount of protein at a concentration of 5-6 M, and nothing at all at lower concentrations. 5 M phosphoric acid was an exception to the results of the weak acids in general, and cleaved large amounts of the His<sub>6</sub>-Z05494 molecule. Figure 2 is a diagram from the HPLC/MSD analysis of the sample treated with 5 M phosphoric acid, and the major component is observed to be the cleaved molecule. However, small amounts of uncleaved molecules and modified cleaved molecule were also detected in the sample.

**[0070]** Nitric acid was too powerful for the cleavage experiment, cutting the protein irregularly. Trifluoroacetic acid did not cut the protein at the cleavage site, which led to results that were hard to interpret. Sulfuric acid and hydrochloric acid showed similar results. At lower concentrations, i.e. from around 1 to 3 M acid, the majority of the protein was cleaved. The results of the HPLC/MSD analysis confirm that the His<sub>6</sub>-Z05494 molecule was cleaved, but the outcome was far from perfect and indicated that the cleavage experiments were not optimal. In almost every case, a significant amount of cleaved molecule with an extra mass of +216 Da was detected.

**[0071]** The results with phosphoric acid and hydrochloric acid were most favorable, and further experiments were performed with these two acids. Dilution series for HCl with the concentrations 7 M, 6 M and 4 M and for H<sub>3</sub>PO<sub>4</sub> with the concentrations 12 M, 10 M and 8 M

were made. A different buffer (2 M  $\text{NaH}_2\text{PO}_4$ , pH 7.4) was used to determine if the Tris buffer could have resulted in modification of the His<sub>6</sub>-Z05494 molecule. The cleavage was carried out at 100 °C, 80 °C and 50 °C and stopped after 1 h, 2 h, 4 h, 6 h and 8 h by increasing the pH through addition of an appropriate concentration of NaOH and 125  $\mu\text{l}$  2 M  $\text{NaH}_2\text{PO}_4$ , pH 7.4. The samples were analyzed on SDS-PAGE gel and loaded onto an HPLC/MSD equipment.

**[0072]** Mass spectrometry confirmed that the temperatures 100 °C and 80 °C were clearly too high for chemical cleavage and resulted in a totally fragmented protein with both acids. The cleavage performed at 50 °C gave better results but confirmed that when a high concentration of  $\text{NaH}_2\text{PO}_4$  was used as buffer, the outcome of the mass spectroscopy was affected as the phosphate precipitated. The high concentration of phosphate in the samples led to a high degree of modifications on the cleaved His<sub>6</sub>-Z05494 molecule with an extra mass of +79 Da. Cleaved His<sub>6</sub>-Z05494 molecule with a mass of 7269 Da, that is an extra mass of +216 Da, was also detected. The best cleavage results with hydrochloric acid were achieved with the concentration 2 M and 3 M for 1-3 h. With phosphoric acid, the best cleavage was accomplished using 5-6 M acid for 1-4 h. Figures 3 and 4 illustrate diagrams for the best results with hydrochloric acid and phosphoric acid, respectively.

**[0073]** To summarize, the experiments described above show that the DP dipeptide may be successfully cleaved using acid catalyzed hydrolysis, when this dipeptide sequence is present in a spacer preceding a three-helix bundle protein domain, such as the three-helix bundle IgG Fc-binding domain present in the polypeptide according to the invention.

## **Example 2**

### **Design considerations in the preparation of an IgG Fc-binding composition according to the invention**

**[0074]** A pilot experiment is performed in order to assess the optimal length of a polymer linker in an IgG Fc-binding composition according to the invention, with a view to binding two monoclonal antibodies (mAbs) with two IgG Fc-binding polypeptides wherein  $n=1$ , i.e. two single domains, coupled "tail-to-tail" via their respective C<sub>TERM-1</sub> residues onto a poly(ethylene glycol) (PEG) linker. The optimal linker is sufficiently long to enable binding of two mAbs without steric interference, but not long enough to allow both IgG Fc-binding domains to bind the same mAb. Homobifunctional, thiol reactive PEG (Bismaleimide-dPEG) may be purchased from Quanta Biodesign Ltd. The catalogue contains variants having either 3 or 11 ethylene glycol units, but other alternatives are available upon request. A linker of suitable length has been found when the two IgG Fc-binding domains connected by a PEG do not have a preference for binding to the same antibody, but bind to two separate antibodies. Thereby, networks of antibodies and PEG-conjugated IgG Fc-binding domains are enabled.



**[0075]** The optimization experiment preferably starts with an evaluation of the two commercially available linker lengths, and then continues with linkers of intermediate lengths, or with a length of more than 11 ethylene glycol units. The tail-to-tail orientation of the two IgG Fc-binding polypeptides allows separation of the domains by rotation around the same "axis", and hence provides a larger distance between the binding surfaces, compared to a situation wherein there is a "head-to-tail" orientation using a spacer of the same lengths. A "head-to-tail" orientation typically results from recombinant expression of several IgG Fc-binding domains in series, as a multimeric fusion protein separated by peptidic spacers.

**[0076]** An experiment aiming to assess that networks of binding polypeptides and mAbs are obtained is performed using a human IgG1 antibody (or a mixture of human IgG1 antibodies). Following incubation of IgG Fc-binding composition with mAbs under suitable conditions, any complexes formed are analyzed using size exclusion chromatography (SEC), and the result is confirmed by high-molecular weight mass spectrometry analysis. In the SEC experiment, the sizes of the complexes formed are determined by comparison with a size reference standard. Starting from a linker length that yields primarily networks and complexes larger than 1:1 (referring to complexes of one PEG-linked dimer of IgG-binding domains and one IgG molecule), the amount of 1:1 complexes formed with a successively reduced linker length is investigated. The optimal length PEG contains one or two ethylene glycol units less than the length showing a clear increase in the amount of 1:1 complex found. Preferably, a PEG molecule having two units less is used, if this does not result in an increase in 1:1 complex content compared with a molecule having one less ethylene glycol unit. Below a certain length, the linker will be too short to allow network formation.

**[0077]** A second optimization experiment is then performed to assess the optimal length for allowing a trimer (i.e. three monomeric IgG Fc-binding polypeptide domains coupled equidistantly on the same PEG chain) to bind three separate mAbs. The same is then done with a tetramer, investigating binding of four mAbs.

**[0078]** As described in the general section above, the composition according to the invention is suitably connectable to a matrix or chromatography medium. In order to find the optimal length of the polymer linker connecting the composition to the matrix, the starting point is to investigate a linker which is at least as long as the linker between IgG Fc-binding domains. Furthermore, the chemical nature of the group used for attachment to the matrix is preferably different from the maleimide used for conjugation of the IgG Fc-binding domains to the linker polymer. Activation of a reacting group may be done either by base or acid, due to the stability of the polypeptide domain against both conditions. As non-limiting examples of chemistries that may be suitable, Quanta Biodesign Ltd makes PEG having a t-butyl ester as well as tosylate-derivatives that may be activated and used for proprietary chemistry, and azido-PEG that may be used in click-chemistry reactions. Additional alternatives are well known in the art.

## SEQUENCE LISTING

**[0079]**

&lt;110&gt; AFFIBODY AB Abrahmsén, Lars

&lt;120&gt; POLYPEPTIDE

&lt;130&gt; 21051179

&lt;150&gt; EP10155835

&lt;151&gt; 2010-03-08

&lt;160&gt; 9

&lt;170&gt; PatentIn version 3.5

&lt;210&gt; 1

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 1

Pro	Ala	Lys	Phe	Asp	Lys	Glu	Gln	Gln	Asn	Ala	Phe	Tyr	Glu	Ile	Leu
1				5					10					15	

His	Leu	Pro	Asn	Leu	Thr	Glu	Glu	Gln	Arg	Asn	Ala	Phe	Ile	Gln	Lys
			20					25					30		

Leu	Lys	Asp	Glu	Pro	Ser	Gln	Ser	Ala	Glu	Leu	Leu	Ala	Glu	Ala	Lys
		35					40					45			

Gln	Leu	Asn	Glu	Ala	Gln	Ala	Gly	Cys	Asp
50					55				

&lt;210&gt; 2

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 2

Pro	Ala	Lys	Phe	Asp	Lys	Glu	Gln	Gln	Asn	Ala	Phe	Tyr	Glu	Ile	Leu
1				5					10					15	

His	Leu	Pro	Thr	Leu	Thr	Glu	Glu	Gln	Arg	Asn	Ala	Phe	Ile	Gln	Lys
			20					25					30		

Leu	Lys	Asp	Glu	Pro	Ser	Gln	Ser	Ala	Glu	Leu	Leu	Ala	Glu	Ala	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Leu Lys Asp Glu Ala Gln Ala Gly Cys Asp  
 35 40 45

Gln Leu Asp Glu Ala Gln Ala Gly Cys Asp  
 50 55

<210> 3

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> Engineered

<400> 3

Pro Ala Lys Phe Asp Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu  
 1 5 10 15

His Leu Pro Asn Leu Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys  
 20 25 30

Leu Lys Asp Glu Pro Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys  
 35 40 45

Gln Leu Asn Glu Ala Gln Ala Pro Lys Ala Glu Ala Lys Phe Asp Lys  
 50 55 60

Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Thr  
 65 70 75 80

Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys Leu Lys Asp Glu Pro Ser  
 85 90 95

Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys Gln Leu Asn Glu Ala Gln  
 100 105 110

Ala Gly Cys Asp  
 115

<210> 4

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> Engineered

<400> 4

Pro Ala Lys Phe Asp Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu  
 1 5 10 15

His Leu Pro Thr Leu Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys  
 20 25 30

Leu Lys Asp Glu Pro Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys  
 .. .. ..

35                      40                      45  
 Gln Leu Asp Glu Ala Gln Ala Pro Lys Ala Glu Ala Lys Phe Asp Lys  
 50                      55                      60  
 Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Thr Leu Thr  
 65                      70                      75                      80  
 Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys Leu Lys Asp Glu Pro Ser  
 85                      90                      95  
 Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys Gln Leu Asp Glu Ala Gln  
 100                      105                      110  
 Ala Gly Cys Asp  
 115

&lt;210&gt; 5

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 5

Ala Glu Ala Lys Phe Asp Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile  
 1                      5                      10                      15  
 Leu His Leu Pro Asn Leu Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln  
 20                      25                      30  
 Lys Leu Lys Asp Glu Pro Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala  
 35                      40                      45  
 Lys Gln Leu Asn Glu Ala Gln Ala Pro Lys Ala Glu Ala Lys Phe Asp  
 50                      55                      60  
 Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu  
 65                      70                      75                      80  
 Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys Leu Lys Asp Glu Pro  
 85                      90                      95  
 Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys Gln Leu Asn Glu Ala  
 100                      105                      110  
 Gln Ala Gly Cys  
 115

&lt;210&gt; 6

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 6

Ala Glu Ala Lys Phe Asp Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile  
 1 5 10 15

Leu His Leu Pro Thr Leu Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln  
 20 25 30

Lys Leu Lys Asp Glu Pro Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala  
 35 40 45

Lys Gln Leu Asp Glu Ala Gln Ala Pro Lys Ala Glu Ala Lys Phe Asp  
 50 55 60

Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Thr Leu  
 65 70 75 80

Thr Glu Glu Gln Arg Asn Ala Phe Ile Gln Lys Leu Lys Asp Glu Pro  
 85 90 95

Ser Gln Ser Ala Glu Leu Leu Ala Glu Ala Lys Gln Leu Asp Glu Ala  
 100 105 110

Gln Ala Gly Cys  
 115

&lt;210&gt; 7

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 7

Val Asp Ala Lys Tyr Ala Lys Glu Met Arg Asn Ala Tyr Trp Glu Ile  
 1 5 10 15

Ala Leu Leu Pro Asn Leu Thr Asn Gln Gln Lys Arg Ala Phe Ile Arg  
 20 25 30

Lys Leu Tyr Asp Asp Pro Ser Gln Ser Ser Glu Leu Leu Ser Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ser Gln Ala Pro Lys  
 50 55

&lt;210&gt; 8

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 8

Val	Asp	Ala	Lys	Tyr	Ala	Lys	Glu	Met	Arg	Asn	Ala	Tyr	Trp	Glu	Ile
1				5					10					15	

Ala	Leu	Leu	Pro	Asn	Leu	Thr	Asn	Gln	Gln	Lys	Arg	Ala	Phe	Ile	Arg
			20					25					30		

Lys	Leu	Tyr	Asp	Glu	Pro	Ser	Gln	Ser	Ser	Glu	Leu	Leu	Ser	Glu	Ala
		35					40					45			

Lys	Lys	Leu	Asn	Asp	Ser	Gln	Ala	Pro	Lys
	50					55			

&lt;210&gt; 9

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Engineered

&lt;400&gt; 9

Gly	Ser	Ser	His	His	His	His	His	Leu	Gln	Ser	Ser	Gly	Val	Asp
1				5					10				15	

Leu	Gly	Thr	Asp	Pro	Val	Asp	Ala	Lys	Tyr	Ala	Lys	Glu	Met	Arg	Asn
			20					25					30		

Ala	Tyr	Trp	Glu	Ile	Ala	Leu	Leu	Pro	Asn	Leu	Thr	Asn	Gln	Gln	Lys
		35					40					45			

Arg	Ala	Phe	Ile	Arg	Lys	Leu	Tyr	Asp	Glu	Pro	Ser	Gln	Ser	Ser	Glu
	50					55					60				

Leu	Leu	Ser	Glu	Ala	Lys	Lys	Leu	Asn	Asp	Ser	Gln	Ala	Pro	Lys	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

65

70

75

80

Asp

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all

liability in this regard.

**Patent documents cited in the description**

- WO2009146755A [0003]
- WO2009080811A [0004]
- US5143844A [0004]
- EP10155835A [0079]

**Non-patent literature cited in the description**

- **NILSSON B et al.**Protein Eng, 1987, vol. 1, 2107-13 [0003]
- **LINHULT et al.**Proteins, 2004, vol. 55, 2407-16 [0003]
- **SAITO A et al.**Protein Engineering, 1989, vol. 2, 6481-488 [0004]
- **BIRGER JANSSON**PhD Thesis, 1996, 91-7170-656-9 [0005]
- **TAVERNAGOLDSTEIN**J Mol Biol, 2002, vol. 315, 3479-84 [0013]
- **HE et al.**Proc Natl Acad Sci USA, 2008, vol. 105, 3814412-17 [0013]
- **THOMPSON, J.D.HIGGINS, D.G.GIBSON, T.J.**Nucleic Acids Research, 1994, vol. 22, 4673-4680 [0014]
- **S HJERTÉN**Biochim Biophys Acta, 1964, vol. 79, 2393-398 [0038]
- **HOLASH et al.**Proc Natl Acad Sci USA, 2002, vol. 99, 1711393-11398 [0056]

**Patentkrav**

**1.** Immunoglobulin G Fc-region-bindende polypeptid, omfattende aminosyresekvensen:

5           i)  $X_1$ -([spacer1]-KFDKEQQN AFYEIL $X_{17}$ LP $X_{20}$ LTEEQRNAFI QKLKDX $X_{36}$ PSQS  
AELLAEAKQL  $X_{51}$ EAQA-[spacer2]) $_n$ -C<sub>CTERM</sub>-1 $X_{CTERM}$

hvor, uafhængigt af hinanden,

$X_1$  er P;

[spacer1] er en aminosyresekvens bestående af 1-3 aminosyrerester;

10            $X_{17}$  er en hvilken som helst aminosyrerest;

$X_{20}$  er en hvilken som helst aminosyrerest;

$X_{36}$  er E eller A;

$X_{51}$  er en hvilken som helst aminosyrerest;

[spacer2] er en aminosyresekvens bestående af 0-20 aminosyrerester;

15            $X_{CTERM}$  er D;

og

$n$  er 1-4;

**2.** IgG Fc-bindende polypeptid ifølge krav 1, hvor [spacer1] er valgt fra A, AE og AEA.

20

**3.** IgG Fc-bindende polypeptid ifølge et hvilket som helst foregående krav, hvor  $X_{17}$  er H.

**4.** IgG Fc-bindende polypeptid ifølge et hvilket som helst foregående krav, hvor

25    $X_{20}$  er N eller T.



- 5.** IgG Fc-bindende polypeptid ifølge et hvilket som helst foregående krav, hvor [spacer2] er G.
- 6.** IgG Fc-bindende polypeptid ifølge et hvilket som helst foregående krav, hvor X<sub>51</sub> er N eller D.
- 7.** IgG Fc-bindende polypeptid ifølge et hvilket som helst af de foregående krav, hvor alle aminosyreresterne af [spacer2] er uafhængigt valgt fra A, E, F, G, I, K, L, P, Q, R, S, T og V, især fra A, E, G, K, P, Q, R, S og T, såsom fra G, Q og S.
- 8.** IgG Fc-bindende polypeptid ifølge et hvilket som helst af de foregående krav, der binder til IgG Fc således at K<sub>D</sub>-værdien af interaktionen højest er  $1 \times 10^{-6}$  M, såsom højest  $1 \times 10^{-7}$  M eller højest  $5 \times 10^{-8}$  M.
- 9.** IgG Fc-bindende polypeptid ifølge et hvilket som helst af de foregående krav, der er i stand til at binde til Fc-delen af et humant IgG-molekyle, såsom klasse 1, 2 og 4 af humant IgG.
- 10.** IgG Fc-bindende polypeptid ifølge et hvilket som helst af kravene 1- 9, hvor X<sub>1</sub> er P, og X<sub>CTERM</sub> er D, og hvor aminosyresekvensen i) er valgt fra SEQ ID NO:1-4.
- 11.** Multimer-polypeptid omfattende mindst to underenheder, idet hver underenhed er et polypeptid ifølge krav 1; og et N-terminal-leader-peptid omfattende en D-rest som den sidste rest deraf.
- 12.** IgG Fc-bindende sammensætning, omfattende mindst et, såsom fra et til fire, polypeptider ifølge et hvilket som helst af kravene 1-11, hvert kovalent forbundet med en ikke-peptid, ikke-nukleinsyre linker-polymer via cysteinresten C<sub>CTERM-1</sub>.
- 13.** Fremgangsmåde til isolering af molekyler omfattende IgG Fc fra en prøve, hvilken fremgangsmåde omfatter trinnene:
- (i) at tilvejebringe en væske indeholdende molekyler omfattende IgG Fc;

(ii) at bringe væsken i kontakt med et IgG Fc-bindende polypeptid eller sammensætning ifølge et hvilket som helst af kravene 1-10 og 12, hvorved molekylerne omfattende IgG Fc binder til polypeptidet eller sammensætningen;


5           (iii) at isolere bundne molekyler omfattende IgG Fc fra væsken.

**14.** IgG Fc-bindende polypeptid eller sammensætning ifølge et hvilket som helst af kravene 1- 10 og 12 kovalent forbundet med en uopløselig matrix.


DRAWINGS

SEQ ID NO:	Amino acid sequence	
1	PAKFDKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LNEAQAGCD	
2	PAKFDKEQQ NAFYEILHLP TLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LDEAQAGCD	
3	PAKFDKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LNEAQAPK AEAKFDKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LNEAQAGCD	
4	PAKFDKEQQ NAFYEILHLP TLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LDEAQAPK AEAKFDKEQQ NAFYEILHLP TLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LDEAQAGCD	
5	AEAKFDKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LNEAQAPK AEAKFDKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LNEAQAGC	
6	AEAKFDKEQQ NAFYEILHLP TLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LDEAQAPK AEAKFDKEQQ NAFYEILHLP TLTEEQRNAF IQKLKDEPSQ SAEILAEAKQ LDEAQAGC	
7	VDAKYAKEMR NAYWEIALLP NLTNQKRAF IRKLYDDPSQ SSEILLSEAKK LNSQAPK	
8	VDAKYAKEMR NAYWEIALLP NLTNQKRAF IRKLYDFPSQ SSEILLSEAKK LNSQAPK	
9	GSSHHHHHLL QSSGVDLGTD P VDAKYAKEMR NAYWEIALLP NLTNQKRAF IRKLYDEPSQ SSEILLSEAKK LNSQAPKVD	


FIGURE 1



**FIGURE 2**



**FIGURE 3**



**FIGURE 4**